Contract development and manufacturing organizations (CDMOs) play a critical role in the dynamic landscape of the pharmaceutical industry, providing essential services in drug development and manufacturing, and enabling pharmaceutical and biotech companies to more efficiently bring innovative therapies to market.

One of the most significant shifts continuing to drive the industry is the movement towards patient-centric drug delivery solutions. Catalent, the global leader in optimizing product development, launch, and full life-cycle supply for partners and patients around the world, stands at the forefront of this movement with a strong commitment to patient-centric drug delivery. The company has achieved significant milestones, particularly with its Zydis® orally dissolving tablet (ODT) technology.

Zydis is recognized as the global best-in-class ODT platform, dispersing in the oral cavity in as little as three seconds without the need for water, and offers an easy-to-take alternative to conventional oral tablets. With such ease of use and convenience, Zydis fosters improved patient compliance and adherence, which not only supports better health outcomes for patients but can also lead to increased revenue and market share for drug innovators who are bringing new brands to market.

Revolutionizing Allergy Treatment with Zydis ODT

For over 20 years, Catalent’s partnership with ALK, a global specialty pharmaceutical company focused on allergy, exemplifies the transformative potential of collaborative innovation and a steadfast focus on patient needs. Allergy injection-based therapies typically require patients to go to specialist clinics for monthly subcutaneous injections, which contribute significantly to patient time spent and high medical costs.

An alternative to injections, the integration of Zydis technology into ALK’s sublingual allergy immunotherapy treatments has redefined the standard of care and has provided options aimed at improving the patient experience for allergy sufferers.

The ALK sublingual immunotherapy Zydis tablet portfolio includes treatments for house dust mite, grass, ragweed, Japanese cedar and tree pollen allergies – covering more than 80 percent of people suffering from respiratory allergies around the world. By harnessing the power of Zydis ODT technology, Catalent is not only addressing the challenges of allergy treatment but also setting a new benchmark for patient-centric care.

Catalent continues to explore new frontiers in the broader allergy space, driven by a shared goal of making treatments more accessible, effective and patient-friendly. The success of the collaboration with ALK serves as an inspiring model for how strategic partnerships with CDMOs can catalyze advancements in healthcare, ultimately enhancing patient outcomes and quality of life.

Looking Ahead

Zydis ODT stands out as an innovative drug delivery technology, consistently delivering exceptional value for partners and the patients they serve. Its versatility extends beyond allergy, offering promising avenues for addressing a wide range of therapeutic areas. From neurodegenerative disorders to migraine treatments and gastrointestinal therapies, Zydis ODT offers a patient-centric approach that enhances treatment efficacy and patient compliance.

Embracing advanced drug delivery technologies like Zydis ODT is key to meeting the evolving needs of patients. By leveraging these innovative solutions and by partnering with trusted CDMOs, companies can drive a new era of innovation, unlocking new treatment possibilities and helping patients lead better, healthier lives.